Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Upadacitinib bij RA-patiënt met onvoldoende respons op csDMARD’s: resultaten na 5 jaar
aug 2024 | RA